Literature DB >> 6507031

Heart disease in myasthenia gravis.

H Hofstad, O J Ohm, S J Mørk, J A Aarli.   

Abstract

Patients with myasthenia gravis (MG) may develop heart disease. Our data on 108 MG patients were examined to assess the type and frequency of this. 17 of 108 patients (16%) showed signs of heart disease which could be regarded as MG-related. 11 of these, of whom 5 died suddenly, had clinical symptoms, mainly arrhythmias. Signs of heart disease were most frequent in thymoma patients (5 of 10), and all 3 microscopically examined hearts from these patients showed a focal myocarditis. 44 spinal muscular atrophy patients serving as controls showed a 16% frequency of signs of heart disease of unknown etiology. However, only 1 of 44 spinal muscular atrophy patients (2%) had clinical symptoms as compared to 11 of 108 MG patients (10%). Together with the characteristic focal nature of the myocarditis and the microscopic similarities between lesions of heart and skeletal muscle, this indicates that the heart disease is specifically related to MG.

Entities:  

Mesh:

Year:  1984        PMID: 6507031     DOI: 10.1111/j.1600-0404.1984.tb00817.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

1.  A case of myasthenia gravis with cardiac fibrosis and easily provoked sustained ventricular tachycardia.

Authors:  Aiko Sakamoto; Miyuki Yamamoto; Masao Takahashi; Kohsuke Ajiki; Satoshi Ota; Akimichi Murakami; Makoto Mutou; Kamon Imai; Takahiro Maruta; Hiroaki Yoshikawa; Nobukazu Ishizaka; Hiroshi Yamashita; Yasunobu Hirata; Ryozo Nagai
Journal:  J Cardiol Cases       Date:  2010-02-19

2.  Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients.

Authors:  Yu-Si Chen; Zi-Qi Liu; Rong Chen; Lei Wang; Ling Huang; Xiao Zhu; Tian-Yan Zhou; Wei Lu; Ping Ma
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

3.  Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin.

Authors:  J A Aarli; K Stefansson; L S Marton; R L Wollmann
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

4.  Non-coronary myocardial infarction in myasthenia gravis: Case report and review of the literature.

Authors:  Panagiotis Zis; Stavros Dimopoulos; Vasiliki Markaki; Antonios Tavernarakis; Serafim Nanas
Journal:  World J Cardiol       Date:  2013-07-26

5.  Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

Authors:  J F Owe; A K Daltveit; N E Gilhus
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

6.  Takotsubo cardiomyopathy in myasthaenia gravis crisis confirmed by cardiac MRI.

Authors:  I B Harries; H Levoir; C Bucciarelli-Ducci; S Ramcharitar
Journal:  BMJ Case Rep       Date:  2015-09-28

7.  Cardiac damage in polymyositis associated with antibodies to tissue ribonucleoproteins.

Authors:  W M Behan; P O Behan; J Gairns
Journal:  Br Heart J       Date:  1987-02

8.  Left ventricular long-axis function in myasthenia gravis.

Authors:  Jone Furlund Owe; Einar Skulstad Davidsen; Geir Egil Eide; Eva Gerdts; Nils Erik Gilhus
Journal:  J Neurol       Date:  2008-12-08       Impact factor: 4.849

Review 9.  Heart Disease in Disorders of Muscle, Neuromuscular Transmission, and the Nerves.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

10.  An Overview of Cardiac Management in Neuromuscular Disease.

Authors:  Renee M Hickey; John D Cullen; George M Sachs
Journal:  Open Cardiovasc Med J       Date:  2016-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.